Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.85
-1.6%
$6.89
$4.58
$9.66
$400.10M1.89455,408 shs665,310 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$2.53
-5.2%
$2.42
$1.15
$9.79
$414.17M1.893.94 million shs4.16 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$23.08
+0.0%
$16.37
$10.80
$24.75
$333.96M-0.04142,922 shs193,206 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.87
+1.1%
$2.89
$2.50
$8.32
$86.58M0.98172,366 shs27,454 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+2.18%+7.40%+9.32%+38.54%-6.99%
Humacyte, Inc. stock logo
HUMA
Humacyte
-2.20%+10.33%+19.73%+85.42%-66.87%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-0.56%-2.33%+56.30%+88.17%+71.52%
XBiotech Inc. stock logo
XBIT
XBiotech
-8.39%-5.33%+6.37%-2.41%-54.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CryoPort, Inc. stock logo
CYRX
CryoPort
1.7787 of 5 stars
3.41.00.00.02.22.50.0
Humacyte, Inc. stock logo
HUMA
Humacyte
1.6564 of 5 stars
3.51.00.00.01.70.80.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
3.097 of 5 stars
0.03.00.04.63.62.51.3
XBiotech Inc. stock logo
XBIT
XBiotech
1.6378 of 5 stars
0.04.00.00.02.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.78
Moderate Buy$11.1141.54% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$11.71363.02% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest XBIT, HUMA, CYRX, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/22/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
7/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $14.00
5/13/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.72N/AN/A$7.44 per share1.06
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.57M249.97N/AN/A($0.41) per share-6.17
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,670.99$115.40 per share0.20$9.23 per share2.50
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M21.82N/AN/A$5.98 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$1.29N/AN/AN/A-21.14%-19.55%8/11/2025 (Estimated)

Latest XBIT, HUMA, CYRX, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.15N/AN/AN/A$0.94 millionN/A
8/12/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92N/AN/AN/AN/AN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/13/2025Q1 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Humacyte, Inc. stock logo
HUMA
Humacyte
0.36
3.68
3.28
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
29.15
29.15

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
XBiotech Inc. stock logo
XBIT
XBiotech
30.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Humacyte, Inc. stock logo
HUMA
Humacyte
150155.12 million147.21 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million21.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.85 -0.13 (-1.63%)
Closing price 04:00 PM Eastern
Extended Trading
$7.85 0.00 (0.00%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$2.53 -0.14 (-5.24%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 +0.03 (+0.99%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$23.08 +0.01 (+0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$23.12 +0.04 (+0.15%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.87 +0.03 (+1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$2.88 +0.01 (+0.35%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.